trending Market Intelligence /marketintelligence/en/news-insights/trending/rl9ffgxvzwdbhf_elmmyeq2 content esgSubNav
In This List

ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


ContraVir Pharmaceuticals gets Nasdaq noncompliance notice

ContraVir Pharmaceuticals Inc. said it failed to comply with Nasdaq's $1 minimum bid price per common share.

The company has 180 calendar days, or until Feb. 25, 2019, to regain compliance.

The current notice has no immediate effect on the company's listing.

New Jersey-based ContraVir Pharmaceuticals develops antiviral drugs with a focus on hepatitis B.